Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05740722 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Study acronym: Norseman
StatusRecruiting
PhasePhase 2
Started2023-05-03
View on ClinicalTrials.gov ↗

Amendment history

2024-01-10
Study Status, Contacts/Locations v2
Study sitescontacts updated at 1 of 1 site
2023-06-21
Not Yet Recruiting→Recruiting Study Status, Outcome Measures, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-03-01→confirmed 2023-05-03
Secondary endpoints6 to 7 entries
Time to onset of sustained disability progression over the treatment period
Primary endpoints1 entry, revised
Time to onsetProportion of patients with sustained disability progression over the treatment period
Study sitesdetails revised at 1 of 1 site
2023-02-22
Original filing
The purpose of this study is to assess the safety and efficacy of Nicotinamide riboside (NR) for treatment of patients with progressive multiple sclerosis. The main question it aims to answer is: • Does NR delay disability progression in progressive multiple sclerosis? Participants will be treated with NR or placebo for 30 months,
Trial Details
NCT Number NCT05740722
Lead Sponsor Haukeland University Hospital
Conditions Multiple Sclerosis, Progressive Multiple Sclerosis
Enrollment 300 participants
Start Date 2023-05-03
Primary Completion 2027-08-01 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-01-11